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Abstract 
Preptin is a newly isolated 34 amino acid peptide hormone co-secreted with insulin and amylin from pancreatic 
β-cells as a regulatory element in bone metabolism with an unclear yet mechanism 
Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints 
Two classes of medications are used in the management of RA: fast-acting non-steroidal anti-inflammatory 
drugs and corticosteoids, and slow-acting drugs. Corticosteroids are well known to have several adverse effects 
on bone metabolism.   
Aim 
The aim of the present study is to assess the association of corticostroids when used in the treatment of 
rheumatoid arthritic patients, with circulating preptin, in an attempt to shed a light on the mechanism of induced 
osteoporosis in such patients. 
Subjects and methods 
Ninety subjects were enrolled in this study. Divided into three groups: 
G1= Thirty RA lean patients taking DMARDs + corticosteroids  
G2= Thirty RA lean patients taking DMARDs without corticosteroids  
G3= Thirty healthy weight and aged matched controls 
Circulating serum preptin was measured in all groups using ELISA technique. 
Results 
Results showed that circulating serum preptin was elevated in patients with RA. However it was lower in G1 
than in G2   
In conclusion 
Results showed that preptin was affected in such patients when compared to arthritic patients not treated with 
corticosteroids. This suggests that this newly discovered hormone could be considered as a new marker for bone 
mineral density and osteoporosis. 
 
1. Introduction 
Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints. It is linked 
initially to immunity against an unknown antigen and later to self-maintained inflammatory processes (1).  RA 
pathogenesis involves complex humoral and cellular reactions one of which is infiltration of lymphocytes and 
monocytes into the synovium. These infiltrating cells and synoviocytes release pro-inflammatory mediators, 
including IL-6, which perpetuate inflammation and destruction through effects on other cell types in the 
synovium and peri-articular structures (2) . There is no known definite cure method for RA. However, the goal 
of treatment is to reduce joint inflammation and pain, maximize joint function, and prevent joint destruction and 
deformity (3). 
Two classes of medications are used in the management of RA: the first class include drugs that which 
promote disease remission and prevent progressive joint destruction these are either fast-acting non-steroidal 
anti-inflammatory drugs, or slow-acting drugs such as antimetabolite or antimalarial drugs such as. Methotrexate, 
leflunamide, sulphasalazine, hydroxychloroquine, and biologic agents (TNF-alpha inhibitors and B-cell 
depleting agents). The second class of drugs include those that help reduce inflammation by decreasing the 
action of the body's immune response. Although this effect can help relieve pain and swelling, it may make you 
more susceptible to infection examples are corticosteroids. These are well known to have several adverse effects 
on bone metabolism. One of many is direct inhibition of osteoblast function and may be differentiation (4).  
Bone cells are classified into three primary classes: osteoblasts, osteocytes, and osteoclasts. Osteocytes 
are terminally differentiated osteoblastic lineage cells that are embedded into a matrix of deposited minerals (5). 
Osteoblasts localize on bone surfaces and promote bone formation by secreting proteins, such as osteocalcin and 
osteopontin, to anchor serum minerals within the bone matrix (6). The mesenchymal bone marrow cells are the 
osteoblast precursor cells, although these pluripotent cells can also differentiate into other cell types like 
adipocytes, chondrocytes, and muscle cells (7). 
Preptin is a newly isolated 34 amino acid peptide hormone co-secreted with insulin and amylin from 
pancreatic β-cells as a regulatory element in bone metabolism with an unclear yet mechanism (8). It is a novel 
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peptide with a direct effect on the action of RUNX2 (a transcriptional factor associated with osteoblasts 
differentiation and marrow stroma cells).(3). Preptin corresponds to Asp69-Leu102 of pro-IGF-IIE peptide (9). 
The prime functions of preptin include regulating carbohydrate, lipid and protein metabolisms by moderating 
glucose-mediated insulin release.(10)Preptin, similar to other products of the pancreatic cell, insulin and amylin, 
stimulate osteoblast proliferation (11). 
To date very few articles have been published on the significance of preptin in 2.humans (12); however 
none of these were conducted on RA patients.  
 
2. Aim 
The aim of the present study is to assess the association of corticostroids when used in the treatment of 
rheumatoid arthritic patients, with circulating preptin, in an attempt to shed a light on the mechanism of induced 
osteoporosis in such patients. 
 
3. Subjects and methods 
This study was conducted at Baghdad Teaching Hospital (Rheumatology Clinic and Teaching Laboratories) 
during the period from September 2014 to February 2015. 
Sixty patients were enrolled in this study. Their consent and approval were taken after through 
description of the nature of the research. All patients were identified and diagnosed as having RA according to 
the ACR criteria.   
The patients were selected according to specific criteria designed by the researchers in which they all 
must be on therapeutic medication for a period not less than 12 months and not more than 18 months. All should 
have lean body weight. 
These patients were divided into two groups according to their drug administration: 
1. Group 1 (G1)= patients on non-steroidal anti-inflammatory drugs 
2. Group 2 (G2)= patients on corticosteroids 
Thirty healthy volunteers were also included in this study. They were recruited from staff members and 
colleagues and were subjected to a thorough physical examination to exclude any diseased individual. They were 
all aged and weight matched. These were Group3 (C).     
Three milliliters of venous blood were aspirated using disposal syringes. Samples were collected 
between(09.00 am-12.00 pm).The blood was allowed to clot in plain tubes for (30 to 45) minutes at room 
temperature and the serum recovered by centrifugation at (3000 rpm) for (10 minutes) and transferred into plain 
plastic tubes and kept frozen at (-20cº) until time of assay. 
 
Serum preptin assay:  
Principle of the Assay: The ELISA kit uses Sandwich-ELISA as the method. The micro ELISA plate provided in 
the kit is pre-coated with an antibody specific to Preptin. Standards or samples are added to the appropriate 
micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody 
specific for Preptin and Avidin-Horseradish Peroxidase (HRP) conjugate is added to each micro plate well 
successively and incubated. Free components are washed away. The substrate solution is added to each well. 
Only those wells that contain Preptin, biotinylated detection antibody and Avidin-HRP conjugate will appear 
blue in color. The enzyme-substrate reaction is terminated by the addition of a sulphuric acid solution and the 
color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm +/- 2 
nm. The OD value is proportional to the concentration of Preptin.   
The kit was supplied by MyBioSource, Inc. located in San Diego, California, USA. 
Descriptive analysis is used to show the mean, standard deviation for BMI, and preptin in all groups. 
 
4. Results 
Sixty RA patients were included in this study. The age range was between 45-75 years. 
Thirty healthy volunteers’ age and gender matched were included as the control group. There was no significant 
difference between the groups regarding gender, age or their body mass index (BMI). 
RA patients had significantly higher preptin serum level than the controls as seen in Table (1).  
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Table (1): Body mass index and serum preptin level in the studied groups 
 
No significant differences were found in serum preptin levels between patient groups subdivided according to 
their therapeutic medications as seen in Table (2) & Figure (1).  
Table (2): Serum preptin level in the patients sub groups. 
 
G1= patients on non-steroidal anti-inflammatory drugs, G2= patients on corticosteroids  
 
 
Figure (1): Body mass index and serum preptin level in the studied groups. BMI = Body mass index, G1= 
patients on non-steroidal anti-inflammatory drugs, G2= patients on corticosteroids  
 
5. Discussion 
Rheumatoid arthritis is a systemic chronic inflammatory disease.  A certain correlation has been observed 
between chronic inflammatory conditions and resistance to insulin actions (3). 
None of the therapies used in treatment of RA showed any correlation studies as to their impact on 
insulin resistance (13). 
However some studies agreed with the hypothesis that corticosteroids are responsible for glucose 
intolerance (14).  
On the other hand several other studies showed that there is only a discrete or a nonexistent relationship 
between corticosteroids and the presence of insulin resistance in patients with RA. These data suggest that their 
beneficial effect on inflammation counteracts their effect on insulin resistance (15).  
This study showed a highly significant increase in serum preptin in diseased groups compared to the 
healthy ones (106.8 vs 423.65 ng/dl). This may be due to the inflammatory effect of RA on the pathogenesis of 
insulin resistance. 
Inflammatory blockade improves pancreatic islet function and the proinflammatory cytokines 
associated with RA induce beta cell toxicity and predispose to insulin resistance (16). Preptin increases glucose-
mediated insulin secretion (Preptin derived from proinsulin-like growth factor II (proIGF-II) is secreted from 
pancreatic islet beta-cells and enhances insulin secretion (17). 
However comparing serum preptin levels in the two RA patients groups, G2 showed higher preptin 
level than G3. This might be due to the fact these patients have impaired preptin secretion that will overall effect 
bone remodeling. Preptin signals osteoblast proliferation through a G protein-coupled receptor that activates Gi-
dependent phosphorylation of p42/44 MAP 
Kinases. Activation of p42/44 MAP kinases (ERKs) is a common feature of proliferative signals 
initiated by a variety of extracellular agents (18).  
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A prevalence of osteoclastic bone resorption over osteoblastic bone formation increases a risk of 
development of osteopenia or osteoporosis. Osteoporosis is well known as a bone metabolic disease associated 
with high risks for bone fractures that often lead to prolonged incapacitation, although patients may be unaware 
of the disease because of a lack of clear symptoms (19). In aging population both genders have risk developing 
osteoporosis (20). Osteoporosis may be also caused by a side effect of glucocorticoid treatment of autoimmune 
diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) (21). 
As it is well known that GC exposure alters the fragile balance between osteoclast and osteoblast 
activity in bone metabolism. GC stimulates osteoclast-mediated bone resorption and reduces osteoblast-mediated 
bone formation, which results in increased overall net bone resorption (4). 
One of the risk factors associated with glucocorticoid-induced osteoporosis is the activity of the 11β-
hydroxysteroid dehydrogenase (11β-HSD) system, a prereceptor modulator of glucocorticoid action (22). Two 
isoenzymes are involved, 11β-HSD1 and 11β-HSD2, catalyze conversion between hormonally active 
glucocorticoids (e.g., cortisol or prednisolone) and inactive glucocorticoids (e.g., cortisone or prednisone). The 
11β-HSD1 enzyme is an activator, and the 11β-HSD2 enzyme is an inactivator. The increased risk of fracture 
with glucocorticoid administration in the elderly may be explained in part by the increase in 11β-HSD1 that 
occurs with aging (21). The risk of glucocorticoid-induced osteoporosis appears to be similar in men and women 
and among various ethnic groups (23).  Impaired preptin could add to this equation or it could be involved 
indirectly in the mechanism of osteoblast inhibition by glucocorticoid treatment 
 
6. Conclusion 
This study was designed to investigate the possibility of considering preptin as a potential marker for bone 
disorders in patients with RA treated with corticosteroids. Results showed that preptin was affected in such 
patients when compared to arthritic patients not treated with corticosteroids. This suggests that this newly 
discovered hormone could be considered as a new marker for bone mineral density and osteoporosis.  
 
References 
McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007 Jun; 
7(6):429-42. 
Jean-Michel Dayer and Ernest Choy  “Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor” 
Rheumatology (Oxford) January 1, 2010 vol. 49 no. 1: 15-24 
Cornish J, Callon KE, Bava U, et al. "Preptin, another peptide product of the pancreatic beta-cell, is osteogenic 
in vitro and in vivo". Am J Physiol Endoc M 2007, 292:E117–E122. 
Mitra R. Adverse effects of corticosteroids on bone metabolism: a review. Physical Medicine and Rehabilitation 
2011 May;3(5):466-71. 
Bonewald LF Osteocytes as dynamic multifunctional cells. Ann N Y Acad Sci. 2007 Nov; 1116:281-90. 
Karsenty G How many factors are required to remodel bone? Nat Med. 2000 Sep; 6(9):970-1. 
Cristancho AG, Lazar MA, Forming functional fat: a growing understanding of adipocyte differentiation. Nat 
Rev Mol Cell Biol. 2011 Sep 28; 12(11):722-34. 
Li N, Zheng Y, Han J, et al. "Lower circulating preptin levels in male patients with osteoporosis are correlated 
with bone mineral density and bone formation. BMC Musculoskeletal Disorders 2013, 14:49-53. 
Buchanan CM, Phillips AR, Cooper GJ. Preptin derived from proinsulin-like growth factor II (proIGF-II) is 
secreted from pancreatic islet beta-cells and enhances insulin secretion. Biochem J 2001, 360: 431–439. 
Bollag RJ, Zhong Q, Ding KH, et al. Glucose-dependent insulinotropic peptide is an integrative hormone with 
osteotropic effects. Mol Cell Endocrinol 177: 35–41, 2001. 
Cornish J, Callon KE, Cooper GJ, Reid IR. Amylin stimulates osteoblast proliferation and increases mineralized 
bone volume in adult mice. Biochem Biophys Res Commun 207, 1995: 133–139. 
Aydin S. Three new players in energy regulation: preptin, adropin and irisin. Peptides. 2014 Jun;56:94-110. 
Dessein PH, Joffe BI, Stanwix AE, Christian BF, Veller M. Glucocorticoids and insulin sensitivity in rheumatoid 
arthritis. J Rheumatol 2004;31:867–74. 
Pagano G, Bruno A, Cavallo-Perin P, Cesco L, Imbimbo B. Glucose intolerance after short-term administration 
of corticosteroids in healthy subjects. Prednisone, deflazacort, and betamethasone.  Arch Intern Med. 
1989 149(5): 1098-101. 
Svenson KL, Lundqvist G, Wide L, Hallgren R. Impaired glucose  handling in active rheumatoid arthritis: effects 
of corticosteroids and antirheumatictreatment. Metabolism. 1987;36:944-8.   
Yang Z, Chen M, Ellett JD, Carter JD, Brayman KL, Nadler JL. Inflammatory blockade improves human 
pancreatic islet function and viability. Am J Transplant 2005;5:475–83. 
Yang G1, Li L, Chen W, Liu H, Boden G, Li K. Circulating preptin levels in normal, impaired glucose tolerance, 
and type 2 diabetic subjects. Ann Med. 2009;41(1):52-6. 
Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9, 1997: 180–186. 
Journal of Natural Sciences Research                                                                                                                                                www.iiste.org 
ISSN 2224-3186 (Paper)   ISSN 2225-0921 (Online) 
Vol.6, No.4, 2016 
 
67 
Rosen CJ, Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2005 Aug 11; 353(6):595-603 
Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocr Rev. 2008 Jun; 29(4):441-64. 
Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med. 2011 Jul 7; 365(1):62-70. 
Cooper MS, Rabbitt EH, Goddard PE, Bartlett WA, Hewison M, Stewart PM. Osteoblastic 11β-hydroxysteroid 
dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J Bone Miner Res 
2002;17:979-986 
Curtis JR, Westfall AO, Allison JJ, et al. Longitudinal patterns in the prevention of osteoporosis in 
glucocorticoid-treated patients. Arthritis Rheum 2005;52:2485-2494 
 
 
 
